Company Of The Day: Merck

+17.19%
Upside
86.78
Market
102
Trefis
MRK: Merck logo
MRK
Merck

What?

Merck (NYSE: MRK) announced an agreement with Singapore to provide access to its experimental oral Covid-19 antiviral drug, molnupiravir. Australia has already ordered 300,000 courses of the drug, while Thailand, South Korea, Taiwan, and Malaysia are also in talks to buy the drug.

Why?

Relevant Articles
  1. Is Humira Maker A Better Bet Over Merck Stock?
  2. Should You Buy Merck Stock After An Upbeat Q2?
  3. Will Merck Stock Rise After Its Q2 Results?
  4. What’s Happening With Merck Stock?
  5. Is There A Better Pick Over Merck Stock In Animal Health Space?
  6. Will Merck Stock Rise After Its Q1 Results?

Merck provided promising interim updates on the experimental oral Covid-19 drug last week, noting that it cut the risk of hospitalization or death by 50% for patients with mild-to-moderate Covid-19. This indicates that the drug could emerge as an important tool in the fight against Covid-19.

So What?

Merck stock has gained almost 8% since the interim data from the trials of the drug were announced late last week and we think the stock has further upside, given the strong prospects of the new drug and Merck’s other products.

See Our Complete Analysis For Merck

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates